日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study

根据同源重组缺陷状态分层的三阴性乳腺癌患者接受基于艾立布林的新辅助化疗的长期疗效：随机JBCRG-22研究的结果

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-026-07917-5
Masuda, Norikazu; Yasojima, Hiroyuki; Bando, Hiroko; Yamanaka, Takashi; Shigematsu, Hideo; Takahashi, Masato; Nagai, Shigenori E; Ito, Mitsuya; Aruga, Tomoyuki; Tokiwa, Mariko; Imoto, Shigeru; Nakamura, Rikiya; Ishiguro, Hiroshi; Kawabata, Hidetaka; Saji, Shigehira; Haga, Hironori; Morita, Satoshi; Toi, Masakazu
BCR
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

更正：帕博西尼联合内分泌治疗对一线或二线治疗的 HR+/HER2- 晚期乳腺癌日本患者的总生存期：一项多中心观察性研究（P-BRIDGE 研究）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01787-3
Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Masuda, Hiroko; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Muramatsu, Yasuaki; Kosaka, Nobuyoshi; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group

日本老年HR+/HER2-晚期乳腺癌患者接受帕博西尼联合内分泌治疗的真实世界疗效：P-BRIDGE研究按年龄分组的亚组分析

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01812-5
Masuda, Hiroko; Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Oda, Hirotaka; Muramatsu, Yasuaki; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

曲妥珠单抗-帕妥珠单抗联合艾立布林或紫杉烷类药物作为人表皮生长因子2阳性局部晚期/转移性乳腺癌的一线化疗方案：随机非劣效性III期EMERALD试验

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-24-01888
Yamashita, Toshinari; Saji, Shigehira; Takano, Toshimi; Naito, Yoichi; Tsuneizumi, Michiko; Yoshimura, Akiyo; Takahashi, Masato; Tsurutani, Junji; Iwatani, Tsuguo; Kitada, Masahiro; Tada, Hiroshi; Mori, Natsuko; Higuchi, Toru; Iwasa, Tsutomu; Araki, Kazuhiro; Koizumi, Kei; Hasegawa, Hiroki; Uchida, Yohei; Morita, Satoshi; Masuda, Norikazu
Human
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-24-01673
Yamamoto, Yutaka; Iwata, Hiroji; Saji, Shigehira; Takahashi, Masato; Yoshinami, Tetsuhiro; Ueno, Takayuki; Toyama, Tatsuya; Yamanaka, Takashi; Takano, Toshimi; Kashiwaba, Masahiro; Tsugawa, Koichiro; Hasegawa, Yoshie; Tamura, Kenji; Tada, Hiroshi; Hara, Fumikata; Fujisawa, Tomomi; Niikura, Naoki; Taira, Naruto; Morita, Satoshi; Toi, Masakazu; Ohno, Shinji; Masuda, Norikazu
肿瘤
肿瘤免疫
信号转导
乳腺癌
Human
发表日期：2025
文献求助 收藏

Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

更正：帕妥珠单抗再治疗人表皮生长因子受体2阳性局部晚期/转移性乳腺癌（PRECIOUS研究）：最终总生存期分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-00722
Yamamoto, Yutaka; Iwata, Hiroji; Saji, Shigehira; Takahashi, Masato; Yoshinami, Tetsuhiro; Ueno, Takayuki; Toyama, Tatsuya; Yamanaka, Takashi; Takano, Toshimi; Kashiwaba, Masahiro; Tsugawa, Koichiro; Hasegawa, Yoshie; Tamura, Kenji; Tada, Hiroshi; Hara, Fumikata; Fujisawa, Tomomi; Niikura, Naoki; Taira, Naruto; Morita, Satoshi; Toi, Masakazu; Ohno, Shinji; Masuda, Norikazu
肿瘤
肿瘤免疫
信号转导
乳腺癌
Human
发表日期：2025
文献求助 收藏

Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey

辅助S-1联合内分泌治疗ER阳性、HER2阴性原发性乳腺癌：POTENT试验后预后调查

期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-025-00832-w
Takada, Masahiro; Saji, Shigehira; Ueno, Takayuki; Masuda, Norikazu; Ishiguro, Hiroshi; Ishida, Takanori; Saeki, Toshiaki; Imoto, Shigeru; Ohno, Shinji; Iwata, Hiroji; Sugie, Tomoharu; Aogi, Kenjiro; Takayama, Shin; Sato, Nobuaki; Kai, Yuichiro; Kitada, Masahiro; Nakamura, Rikiya; Watanabe, Kenichi; Matsuyama, Yutaka; Toi, Masakazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Precision Oncology Framework Using Circulating Tumor Cells

利用循环肿瘤细胞的精准肿瘤学框架

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms26125539
Kakizaki, Fumihiko; Oshiro, Kyoichi; Enoki, Yuya; Kawanishi, Kana; Masuda, Norikazu; Maekawa, Hisatsugu; Matsubayashi, Jun; Kawashima, Masahiro; Miyoshi, Hiroyuki; Takemura, Yukitoshi; Obama, Kazutaka
肿瘤细胞
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Dynamic predictive power of TP53 signatures in breast cancer prognosis: Pre- and post-neoadjuvant chemotherapy insights

TP53 特征在乳腺癌预后中的动态预测能力：新辅助化疗前后的启示

期刊:Translational Oncology
影响因子:4.1
doi:10.1016/j.tranon.2025.102398
Sasaki, Keiju; Takahashi, Shin; Ouchi, Kota; Shirota, Hidekazu; Sato, Nobuaki; Kaneko, Kouji; Masuda, Norikazu; Fujishima, Fumiyoshi; Sato, Satoko; Ishioka, Chikashi
肿瘤
P53
乳腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer

基因组确定的亚型和临床病理特征作为预测早期HER2阳性乳腺癌术前化疗联合HER2靶向治疗疗效的指标

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-15133-5
Imamura, Sayumi; Mori, Kiyoshi; Yasojima, Hiroyuki; Mizutani, Makiko; Okada, Kumiko; Hayashi, Chie; Mano, Masayuki; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏